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Abstract
Background Hepatoblastoma (HB) and pediatric hepatocellular carcinoma (HCC) are the most common malignant liver 
tumors in childhood. Both tumor types exhibit genetic and epigenetic alterations in the WNT/β-catenin signaling pathway, 
which is a key regulator of liver progenitor cells in embryonic development. The tumors demonstrate a high rate of β-catenin 
mutations and gene expression changes of several WNT antagonists. However, the role of the WNT inhibitory factor secreted 
frizzled-related protein 1 (SFRP1) has not been addressed in pediatric liver cancer so far.
Results In our study, we investigated the gene expression level, DNA methylation status and functional relevance of SFRP1 
in HB cell lines and in pediatric liver tumor patient samples. SFRP1 was downregulated due to DNA promoter methylation 
in all tested HB cell lines. Overexpression of SFRP1 in HB cell lines diminished tumor cell proliferation, colony formation 
and migration potential. In addition, the SFRP1-expressing HB cell lines showed reduced WNT/β-catenin signaling pathway 
activity and decreased expression of WNT target genes. To evaluate the utility of SFRP1 as a biomarker in pediatric liver 
cancer, we determined the gene expression level and DNA methylation status of SFRP1 in 45 pediatric liver tumor patient 
samples. The correlation analysis of different clinical parameters and tumor characteristics revealed a significant correlation 
of reduced SFRP1 expression with the presence of mutant β-catenin. The methylation status of SFRP1 was furthermore 
associated to a pediatric liver tumor type with HCC-like characteristics, TERT mutations and an older age at diagnosis.
Conclusion Altogether, our data demonstrate that the epigenetic suppression of the WNT/β-catenin antagonist SFRP1 has 
an important impact on the malignant behavior of HB cells. Although SFRP1 methylation is a common event in HCC-like 
pediatric liver tumors, its potential as a prognostic or diagnostic biomarker needs to be further investigated.
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Background
Hepatoblastoma (HB) is the most common malignant liver 
tumor in children under the age of 4 years and its incidence 
has increased over the last decades (Kremer et al. 2014). 
Hepatocellular carcinoma (HCC) has also been described in 
the pediatric population, but the tumor occurs more rarely 
than HB and predominantly manifest in older children or 
young adults (Ng and Mogul 2018). Although the survival 
rates of pediatric HB and HCC have improved up to 80% 
over the last decades, due to advanced surgical techniques 
and chemotherapeutic treatments, there are still HB patient 
subgroups with a dismal prognosis (Tulla et  al. 2015; 
Khanna and Verma 2018; Czauderna and Garnier 2018). 
Particularly, children presenting with non-resectable tumors, 
chemotherapy resistance, or metastasis show reduced sur-
vival rates (Czauderna et al. 2016). Consequently, a more 
profound understanding of the biology of HB will help to 
uncover mechanisms promoting cancer development and 
progression.
HBs often exhibit an epithelial or mixed morphologi-
cal subtype and show two distinct transcriptomic profiles, 
which are classified as 16-gene signature cluster C1 or C2 
(Perugorria et al. 2019). Although C1 and C2 HBs differ 
in their tumor characteristics, they exhibit common genetic 
aberrations affecting the WNT/β-catenin/AXIN signaling 
(Cairo et al. 2008). The canonical WNT/β-catenin signaling 
pathway regulates the proliferation, maturation and survival 
of liver progenitor cells in embryogenesis. Notably, the path-
way is often constitutively activated in HB and HCC devel-
opment (Russell and Monga 2018). Stabilizing mutations in 
the β-catenin (CTNNB1) gene occur with a frequency of up 
to 37% in HCC and 60–70% in HB and as a consequence, 
β-catenin accumulates in the nucleus and regulates the 
expression of target genes (Zucman-Rossi et al. 2015; Bell 
et al. 2017). Further genetic alterations involve loss-of-func-
tion mutations in the APC regulator of WNT signaling path-
way (APC), AXIN1 and AXIN2 genes, which prevents a pro-
teasomal degradation of β-catenin (Perugorria et al. 2019). 
Moreover, it was previously shown that the dickkopf WNT 
signaling pathway inhibitor 1 (DKK1) is upregulated in HB 
patient samples, which might represent negative feedback 
mechanisms (Wirths et al. 2003). On the contrary, among 
the known WNT antagonists, the secreted frizzled-related 
protein 1 (SFRP1) is often downregulated in various cancer 
entities, which indicates that SFRP1 has tumor-suppressive 
functions (Vincent and Postovit 2017). Under physiological 
conditions, SFRP1 inactivates the canonical and non-canon-
ical WNT/β-catenin pathway by directly binding to WNT 
proteins or the frizzled receptor (Kawano and Kypta 2003). 
Thus, a downregulation of SFRP1 in HCC cells resulted 
in stimulated WNT signaling activity and increased tumor 
cell growth (Shih et al. 2007). Importantly, during breast 
and prostate cancer development SFRP1 expression is lost 
due to epigenetic silencing, induced by an enrichment of 
DNA methylation in the promoter region (Lodygin et al. 
2005; Lo et al. 2006). Notably, promoter methylation of 
SFRP1 was also identified as a common event in adult HCC 
(Huang et al. 2007; Shih et al. 2006). Since SFRP1 sup-
pression contributes to elevated WNT/β-catenin signaling, 
which is a known characteristic of HB and HCC, we were 
highly interested in the functional role of SFRP1 in pedi-
atric liver cancers. Thus, we investigated the SFRP1 DNA 
methylation status and gene expression levels in HB cell 
lines and primary pediatric liver tumor samples. Overex-
pression of SFRP1 in HB cell lines resulted in an inhibition 
of tumor cell growth, colony formation and migration and 
a decrease in WNT/β-catenin signaling activity. Moreover, 
SFRP1 promoter methylation and transcriptional silencing 
was identified in a subset of primary pediatric liver tumors. 
Our findings indicate that the epigenetic suppression of 
SFRP1 represents an alternative mechanism for enhancing 
WNT/β-catenin signaling in the development of pediatric 
liver cancer, particularly in children diagnosed at older ages.
Methods
Patients
Liver tumor specimens of 45 patients and matching normal 
liver tissue from seven patients (N110, N146, N198, N175, 
N227, N253, N612) were obtained from pediatric patients 
undergoing surgical resection in the Department of Pediatric 
Surgery, University Hospital, LMU Munich, Germany. Each 
patient gave written informed consent and the study proto-
col was approved by the Committee of Ethics, LMU Munich. 
Clinicopathological parameters and experimental data of 
all patient samples are listed in the Supplementary Table 1. 
Experimental data of SFRP1 expression were categorized into 
low (< 1) and high (> 1) and correlated to different clinico-
pathological parameters. A similar correlation analysis was 
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performed for the SFRP1 methylation status (M methylated, 
U unmethylated).
Cell culture and DNA methylation inhibitor 
treatment
The hepatoblastoma cell lines HuH-6 (RRID:CVCL_4381), 
HepT1 (RRID:CVCL_G003), Hep-T3 (RRID:CVCL_
G004), and HepG2 (RRID:CVCL_0027) were cultured in 
RPMI 1640 growth media (Gibco, Thermo Fischer Scien-
tific, Germany), supplemented with 10% fetal calf serum, 
100  U/mL penicillin, and 100  μg/mL streptomycin, at 
37 °C in a humidified chamber with a saturated atmosphere 
containing 5%  CO2. Cells were passaged at a confluency 
of 80–90% with 0.05% trypsin (v/v) and 0.2% EDTA (w/v) 
(Sigma-Aldrich, Germany) in Dulbecco’s phosphate-buff-
ered saline (PBS). For gene expression and methylation 
analysis Huh-6 and Hep-T3 cells were treated with 0.5 µM 
5-aza-2′-deoxycytidine (5-aza; Sigma-Aldrich, Germany), 
HepT1 and HepG2 cells with 1.25 µM 5-aza or solvent for 
3 and 5 days.
Cell transfection
HuH-6, HepT1 and HepG2 cells (5 × 105 cells/six-well plate) 
were transfected with 1 μg DNA of the pcDNA3.1/V5-HisA 
control vector (#V81020, Thermo Fischer Scientific, Ger-
many) or the pcDNA3.1-SFRP1 (pSFRP1) expression vec-
tor containing full-length SFRP1 cDNA (Fukui et al. 2005) 
using FuGene 6 transfection reagent (Roche Diagnostics, 
Germany) according to the manufacturer’s protocol. For 
stable transfection, cells were incubated in selection media 
24 h after transfection containing 200 µg/ml G418 (Sigma-
Aldrich, Germany). Two weeks after G418 selection, 
resistant colonies were picked and cultured under standard 
medium conditions.
Cell viability assay
2000 stably or transiently transfected HuH-6, HepT1 and 
HepG2 cells were seeded in a 96-well plates in RPMI 1640 
growth media and cell proliferation was measured at the 
indicated time points using the Cell Proliferation Kit I 
(Roche Diagnostics) according to the manufacturer’s proto-
col. The absorbance of the colorimetric reaction was quanti-
fied on the GENios reader (Tecan, Switzerland) by measur-
ing at a wavelength of 595 nm. Cell growth was normalized 
to the zero hour time points.
Colony formation assay
5000 stably transfected HuH-6 and HepG2 cells were seeded 
in a six-well plate. Cells grew for 10 days in RPMI 1640 
growth media. After methanol fixation, cells were stained 
with 0.05% crystal violet in 20% methanol and washed with 
tap water. Colonies were counted and are represented as 
number of colonies per well.
Cell migration assay
Stably transfected HuH-6 cells were seeded into six-well 
plates and grown as confluent monolayer. A wound of 
approximately 1 mm was inflicted to the cell monolayer 
using a pipette tip. The cells were washed twice with PBS 
to remove detached cells and incubated for additional 72 h 
in 1% FCS starved RPMI 1640 growth media to diminish 
cell proliferation. Images were taken at 0, 24, 48 and 72 h 
after scratching and the wound widths were measured and 
quantified with ImageJ (Rasband, W.S., ImageJ, US National 
Institutes of Health, Bethesda, USA). Cell migration was 
normalized to the zero hour time points.
TOP/FOP assay
To measure the activity of the canonical WNT/β-catenin 
pathway, we used the TOP/FOP-flash promoter assay (Mil-
lipore, Germany). 1 × 105 stably transfected HuH-6, HepT1 
and HepG2 cells were seeded in a 12-well plate and co-
transfected with FuGene 6 transfection reagent (Roche Diag-
nostics) using the following plasmids: pTOP (Firefly-Lucif-
erase reporter plasmid containing several TCF binding sites) 
or pFOP (Firefly-Luciferase reporter plasmid containing 
mutated TCF binding sites) together with pRL-TK (Renilla-
Luciferase control plasmid to normalize transfection effi-
ciency). The luciferase activity was measured with the Dual-
Glo™ Luciferase Assay System (Promega, Germany) 48 h 
after transfection according to the manufacturer’s protocol 
on the GENios microplate reader (Tecan).
Immunofluorescence staining
Staining was performed according to standard protocol using 
β-catenin (D10A8) antibody (#8480, cell signaling, USA). 
Negative control was performed with secondary antibody 
only (data not shown).
Immunoblot analysis
Immunoblot analysis was performed according to the man-
ufacturer’s protocol, with the exception that blocking and 
first antibody (SFRP1 (D5A7) #3534, cell signaling, USA; 
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GAPDH, H86504M, Meridian Life Science, USA) incuba-
tion was done in 5% BSA/TBS-T buffer. Secondary antibody 
was incubated in 5% milk/TBS-T.
Quantitative real‑time PCR (qRT‑PCR)
Total RNA was extracted using TriReagent (Sigma-Aldrich, 
Germany) according to the manufacturer’s protocol. Two 
micrograms of RNA was transcribed into cDNA using ran-
dom hexamer primer and SuperScript™ II Reverse Tran-
scriptase (Thermo Fischer Scientific, Germany). Quantita-
tive RT-PCR was performed in doublets using iTaq-SYBR 
Green-Supermix (Bio-Rad, Germany) and the Master cycler 
ep gradient (Eppendorf, Germany) as previously described 
(Eichenmuller et al. 2009). Gene expression primer are pro-
vided in Supplementary Table 2. Expression levels were 
normalized to the housekeeping gene TATA-box binding 
protein (TBP) and the fold change was calculated according 
to the ΔΔCt method in relation to the expression level of 
normal liver tissue. An expression level < 1 represents a low 
and > 1 a high expression.
Methylation analyses
Genomic DNA was isolated by phenol and chloroform 
extraction following standard procedures. As a positive con-
trol for methylated DNA, genomic DNA of a healthy donor 
was artificially methylated using the CpG methyltransferase 
M. SssI (Thermo Fischer Scientific, Germany) according to 
the manufacturer’s instructions. As a negative control for 
unmethylated DNA, HuH-6 cells were treated with 0.5 μM 
5-aza-2′-deoxycytidine (5-aza; Sigma-Aldrich, Germany) for 
72 h and genomic DNA was isolated. Genomic DNA was 
bisulfite-treated using the EpiTect® Bisulfite Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol. 
The methylation status of APC, DKK1, SFRP1 and WIF1 
was analyzed by methylation-specific-PCR (MSP). MSP 
primer are provided in Supplementary Table 2 (Aguilera 
et al. 2006; Esteller et al. 2000). MSP primer design and 
PCR conditions were previously described (Eichenmuller 
et al. 2009). PCR products were visualized on a 1.5% aga-
rose gel.
Chromatin immunoprecipitation
HuH-6, HepT1 and HepG2 cells were treated with 1.5 µM 
5-aza, 1.5  µM 5-aza plus 0.5  µM Vorinostat (SAHA) 
(SML0061, Sigma-Aldrich, Germany) or dissolvent (DMSO, 
1:1000) for 3 days. Chromatin immunoprecipitation was per-
formed as previously described (Benitz et al. 2019). Here, 
we used the following antibodies: anti-H3K27ac (Acetyl-
Histone H3 (Lys27) (D5E4), #8173, Cell Signaling, USA), 
or IgG control (sc-2027, Santa Cruz Biotechnology, USA). 
Pull-down was done with Protein A agarose/salmon sperm 
DNA (Merck Millipore, Germany). After reverse crosslink-
ing, DNA was purified with the Qiaquick® PCR Purification 
Kit (Qiagen) and two genomic areas around transcriptional 
start side of SFRP1 were amplified and quantified by qRT-
PCR. Analysis of the EPCAM promoter was included as 
quality control to ensure specific enrichment of the acti-
vating histone modifications. Primer sequences are listed 
in Supplementary Table 2. Sample values were calculated 
according to the percent input method.
Statistical analysis
Data are presented as mean ± SEM. Statistical significance 
was determined by two-tailed, unpaired Student’s t test, 
one-way ANOVA with Dunnett’s multiple comparisons test 
or Chi-square test as indicated in the figure legends using 
GraphPad Prism 8 software (GraphPad Software Inc.) or 
R 2.1.0 (https ://cran.r-proje ct.org/src/base/R-2/R-2.1.0.tar.
gz) and R-studio Version 1.1.442. A two-sided significance 
of p < 0.05 was used throughout, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001.
Results
Promoter methylation causes SFRP1 silencing 
in human HB cell lines
Although the WNT/β-catenin signaling pathway is often 
constitutively activated in liver cancer, due to stabilizing 
β-catenin mutations, previous data indicate that an addi-
tional suppression of the WNT antagonist, particularly of 
SFRP1, through epigenetic mechanisms is an important 
event in cancer formation (Kaur et al. 2012). To analyze 
the gene expression status of the known WNT antagonists 
APC, DKK1, SFRP1 and WIF1 in HB, we selected the HB 
cell lines HuH-6, HepT1, Hep-T3 and HepG2 and compared 
the expression levels to normal pediatric liver tissue (NL) 
(Fig. 1a). Here, APC and SFRP1 were downregulated in all 
four HB cell lines. In contrast, DKK1 and WIF1 showed a 
heterogeneous expression pattern, with an increased expres-
sion of DKK1 in HuH-6, HepT1 and Hep-T3 and of WIF1 
in Hep-T3 cells (Fig. 1a). Next, we investigated whether the 
gene expression of APC, DKK1, SFRP1 and WIF1 is epi-
genetically controlled by DNA promoter methylation. For 
this, we performed methylation-specific-PCR (MSP) after 
bisulfite treatment of DNA isolated from HB cell lines and 
identified that all four HB cell lines demonstrated a strong 
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Fig. 1  Promoter methylation causes SFRP1 silencing in human HB 
cell lines. a mRNA expression of APC, DKK1, SFRP1 and WIF1 in 
HuH-6, HepT1, Hep-T3, and HepG2 and normal liver (NL, n = 7) was 
determined by qRT-PCR (n = 3) and calculated as normalized mRNA 
expression (fold change) to normal liver controls. b DNA methyla-
tion status (M methylated, U unmethylated) of APC, DKK1, SFRP1 
and WIF1 promoter regions in HuH-6, HepT1, Hep-T3, and HepG2 
after solvent (Ø), 3 days (3d) and 5 days (5d) 5-aza treatment was 
conducted by MSP. c mRNA expression of APC, DKK1, SFRP1 and 
WIF1 in HuH-6, HepT1, Hep-T3, and HepG2 after solvent (Ø), 3 
days (3d) and 5 days (5d) 5-aza treatment (n = 3) was determined by 
qRT-PCR and summarized as  log2 relative gene expression in heat-
maps. All data are represented as mean ± SEM; p values were calcu-
lated by one-way ANOVA with Dunnett’s multiple comparisons test; 
*p < 0.05, ***p < 0.001, ****p < 0.0001
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DNA promoter methylation of the APC, DKK1, SFRP1 
and WIF1 genes, with an exception for DKK1, which was 
unmethylated in HuH-6 cells (Fig. 1b). Treatment with the 
DNA methylation inhibitor 5-aza-2´-deoxycytidine (5-aza) 
for 3 and 5 days revealed a strong DNA demethylation 
of the analyzed promoter areas in all cell lines (Fig. 1b). 
However, 5-aza treatment did not affect APC expression. 
DKK1 and WIF1, which show originally a high expression 
in HepT1 and/or Hep-T3 cells, were unexpectedly down-
regulated after 5-aza treatment (Fig. 1c). Interestingly, only 
the demethylation of the SFRP1 promoter was associated 
with a consistent restoration of gene expression in all four 
HB cell lines (Fig. 1c). Immunoblot analysis of 5-aza-treated 
HuH6, HepT1 and HepG2 cells revealed increased SFRP1 
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Fig. 2  Restored SFRP1 expression affects WNT signaling activity 
and HB tumor cell characteristics. a mRNA expression of SFRP1 
in transient pcDNA3.1- and pSFRP1-transfected HuH-6 cells after 
48 and 72 h was determined by qRT-PCR and calculated as normal-
ized mRNA expression (fold change) to pcDNA3.1 control (n = 2). 
b Cell growth of transient pcDNA3.1- and pSFRP1-transfected 
HuH-6 cells was assessed by MTT assay at indicated time points. 
Values were normalized to zero hour time point and shown as 
mean ± SEM (n = 2). Slope difference was analyzed by linear regres-
sion, ****p < 0.0001. c mRNA expression and representative immu-
noblot image of SFRP1 in stable pcDNA3.1- and pSFRP1-transfected 
HuH-6 cell clone 2. GAPDH served as loading control in immuno-
blot analysis (n = 2). Gene expression was determined by qRT-PCR 
and calculated as normalized mRNA expression (fold change) to 
pcDNA3.1 control (n = 3). d Cell growth of stable pcDNA3.1- and 
pSFRP1-transfected HuH-6 cells was assessed by MTT assay at indi-
cated time points. Values were normalized to zero hour time point 
and shown as mean ± SEM (n = 4). Slope difference was analyzed 
by linear regression, *p < 0.05. e Representative pictures and quan-
tification of number of colonies per well of stable pcDNA3.1- and 
pSFRP1-transfected HuH-6 cells (n = 3). f Representative pictures 
and quantification of cell migration at indicated time points were 
normalized to zero hour time points. Slope difference was analyzed 
by linear regression, ****p < 0.0001. g TOP/FOP reporter plas-
mid activity was assessed by a relative luciferase activity in stable 
pcDNA3.1- and pSFRP1-transfected HuH-6 cells 48 h after co-trans-
fection (n = 5). h mRNA expression of MYC and CCND1 in stable 
pcDNA3.1- and pSFRP1-transfected HuH-6 cell clone 2 was deter-
mined by qRT-PCR and calculated as normalized mRNA expression 
(fold change) to pcDNA3.1 control (n = 4). i Immunofluorescence 
staining of β-catenin (CTNNB1, green) and DAPI nuclear staining 
(blue) in stable pcDNA3.1- and pSFRP1-transfected HuH-6 cells. 
Scale bars: 100 µm. All data are represented as mean ± SEM; unless 
otherwise stated p values were calculated by two-tailed, unpaired Stu-
dent’s t test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
◂
expression after 3 days (Supplementary Fig. 1a). Moreo-
ver, we analyzed if other epigenetic mechanisms, such as 
histone acetylation, regulate SFRP1 gene expression. The 
5-aza treatment of HuH-6, HepT1 and HepG2 cells alone 
or in combination with an HDAC inhibitor (SAHA) did not 
result in increased histone acetylation levels at two regula-
tory SFRP1 genome sites, as it could be shown for EPCAM, 
which was included as positive control (Supplementary 
Fig. 1b). In conclusion, our data suggest that solely SFRP1 
promoter hypermethylation is associated with a transcrip-
tional silencing in HB tumor cell lines.
Restored SFRP1 expression affects WNT signaling 
activity and HB tumor cell characteristics
To study the functional relevance of SFRP1 gene silencing 
in HB, we assessed tumor cell characteristics after SFRP1 
re-expression. To restore SFRP1 gene expression, we tran-
siently transfected HuH-6, HepT1 and HepG2 cells with 
the pcDNA3.1-SFRP1 plasmid (pSFRP1), containing full-
length SFRP1 cDNA, or with the empty vector (pcDNA3.1) 
as control. Expression levels of SFRP1 were determined 48 
and 72 h after transfection and showed markedly elevated 
SFRP1 transcript levels (Fig. 2a, Supplementary Fig. 2a). 
Notably, transiently pSFRP1-transfected HuH-6, HepT1 and 
HepG2 cells displayed a reduced growth rate compared to 
control-transfected cells (Fig. 2b, Supplementary Fig. 2b). 
To analyze long-term effects, we generated pSFRP1 or 
pcDNA3.1 stably transfected HuH-6, HepT1 and HepG2 
cells. For instance, the HuH-6 cell clone 2 showed a substan-
tial increase in SFRP1 gene and protein expression (Fig. 2c). 
In line with our preceding results, the stable SFRP1 expres-
sion in HuH-6, HepT1 and HepG2 cells resulted in signifi-
cantly impaired tumor cell growth (Fig. 2d, Supplementary 
Fig. 2c) and a strong decrease in colony formation (Fig. 2e, 
Supplementary Fig. 2d) and migration capacity (Fig. 2f) 
compared to control cells. To investigate whether the re-
expression of SFRP1 has a direct influence on the activity 
of the canonical WNT/β-catenin signaling pathway, we per-
formed a TOP/FOP luciferase reporter assay, in which the 
binding activity of ß-catenin to the TOP reporter plasmids is 
measured. Strikingly, the stably pSFRP1-transfected HuH-
6, HepT1 and HepG2 cells revealed a substantial reduction 
in the relative luciferase activity, indicating a suppression 
of the canonical WNT/β-catenin pathway activity (Fig. 2g, 
Supplementary Fig. 2e). To corroborate these findings, 
we additionally measured the expression of WNT target 
genes and observed a significant downregulation of MYC 
and CCND1 in the stably pSFRP1-transfected HuH-6 cells 
(Fig. 2h). Interestingly, the level of β-catenin or its cellular 
localization is not altered in the stably pSFRP1-transfected 
HuH-6 cells, indicating that SFRP1 re-expression abolishes 
the transcriptional activity of β-catenin (Fig. 2i). Altogether, 
our results demonstrate that a restored SFRP1 expression 
has tumor-suppressive effects in HB cells by reducing the 
activity of the canonical WNT/β-catenin pathway.
SFRP1 DNA methylation correlates with the tumor 
type and a late onset of the disease
To uncover the SFRP1 gene expression and DNA methyla-
tion status in primary pediatric liver tumors, we first per-
formed a gene expression analysis on a cohort of 45 patient 
samples, containing 30 HBs, nine HCCs, 2 transitional 
liver cell tumors (TLCT) and 2 nested stromal-epithelial 
liver tumors (NSET) (Supplementary Table 1). Overall, we 
detected a low SFRP1 gene expression in 62% (28/45) of 
cases and the median SFRP1 expression level was reduced 
in tumor tissue compared to normal liver, although the 
difference was not significant (Fig. 3a, b). In addition, we 
determined the SFRP1 DNA methylation status for each 
case with MSP and correlated it to the SFRP1 gene expres-
sion level (Fig. 3b). Notably, 43% of the patient samples 
with low SFRP1 expression showed SFRP1 DNA methyla-
tion. Concomitantly, however, 35% of the patient samples 
with a high SFRP1 expression showed also SFRP1 DNA 
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methylation. Hence, the overall correlation between the 
SFRP1 DNA methylation and transcriptional status was 
not significant (Fig. 3b). Representative results of the MSP 
reactions are illustrated in Fig. 3c. To study the impact of 
the SFRP1 gene expression level on clinical outcome, we 
performed a Chi-square correlation analysis based on a low 
(< 1) and high (> 1) SFRP1 expression and various clinico-
pathological parameters (Table 1). Here, we uncovered that 
the SFRP1 expression is significantly associated with the 
PRETEXT (PRE-Treatment EXTent of tumor) risk classifi-
cation system (Towbin et al. 2018). Particularly, all patient 
samples (6/6) with the unfavorable PRETEXT category 4 
displayed a low SFRP1 gene expression (Table 1). Moreover, 
the transcriptional level of SFRP1 correlated significantly 
with the ß-catenin (CTNNB1) mutation status. Interest-
ingly, patient samples with mutant ß-catenin demonstrated 
a reduction in SFRP1 gene expression, whereas patients 
with wildtype ß-catenin revealed increased SFRP1 expres-
sion levels (Fig. 3d). Since 18 out of 45 patient samples 
exhibited SFRP1 DNA methylation, we performed also a 
Chi-square correlation analysis based on a methylated (M) 
and unmethylated (U) SFRP1 profile (Table 2). The SFRP1 
methylation status was significantly associated with the 
gender, age at diagnosis, tumor type, differentiation, extra-
hepatic growth, resection margin and telomerase reverse 
transcriptase (TERT) mutations (Table 2). The distribution 
of SFRP1-methylated and -unmethylated cases in relation to 
the tumor type clearly showed that most of the HCC/TLCT 
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Fig. 3  SFRP1 DNA methylation correlates with the tumor type and 
late onset of the disease. a mRNA expression of SFRP1 in normal 
liver (NL) and patient tumor samples (TU) was determined by qRT-
PCR and calculated as normalized mRNA expression (fold change) 
to NL controls. The red line marks the median expression level. 
b For each tumor and normal tissue (N—number) sample, the nor-
malized SFRP1 gene expression and promoter methylation status 
is shown. The embedded table displays the distribution of methyl-
ated (M) and unmethylated (U) SFRP1 in the SFRP1 low and high 
gene expression categories. c Representative pictures of the SFRP1 
MSP reaction from selected normal and tumor tissue samples. Sss1-
treated DNA serves as methylated positive control, 5-aza-treated 
DNA as unmethylated control. d Illustration of the correlation analy-
sis of SFRP1 gene expression and β-catenin mutation status, see also 
Table  1. e Illustration of the correlation analysis of SFRP1 DNA 
methylation status to the tumor type, considering only HB and HCC/
TLCT tumors, and to the TERT mutation status, see also Table 2. f 
Forest plot with a simple and cumulative generalized linear regres-
sion model considering SFRP1 methylation status, gene expression 
category and a combined profile in respect to the age at diagnosis
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Table 1  Correlation analysis of 
SFRP1 gene expression SFRP1 expression High (n = 17) Low (n = 28) Total (n = 45) p value
Gender 0.848
 f 8 (47.1%) 14 (50.0%) 22 (48.9%)
 m 9 (52.9%) 14 (50.0%) 23 (51.1%)
Age at diagnosis in month 0.386
 nd 0 1 1
 Mean (SD) 67.867 (72.955) 50.780 (55.905) 57.382 (62.777)
 Range 1.874–199.435 0.000–184.179 0.000–199.435
Outcome 0.758
 DOD 3 (17.6%) 6 (21.4%) 9 (20.0%)
 NED 14 (82.4%) 22 (78.6%) 36 (80.0%)
Cause of death 0.541
 nd 0 1 1
 Progressive 2 (11.8%) 2 (7.4%) 4 (9.1%)
 Recurrence 2 (11.8%) 3 (11.1%) 5 (11.1%)
 Alive 13 (76.5%) 22 (81.5%) 35 (79.5%)
Tumor type 0.170
 HB 10 (58.8%) 20 (71.4%) 30 (66.7%)
 HCC/TLCT 5 (29.4%) 8 (28.6%) 13 (28.9%)
 NSET 2 (11.8%) 0 (0.0%) 2 (4.4%)
Differentiation 0.388
 nd 2 0 2
 Epithelial 6 (40.0%) 17 (60.7%) 23 (53.5%)
 Fibrolamellar 3 (20.0%) 1 (3.6%) 4 (9.3%)
 Well differentiated 0 (0.0%) 2 (7.1%) 2 (4.4%)
 Moderately differentiated 1 (6.7%) 2 (7.1%) 3 (7.0%)
 Mixed 5 (33.3%) 6 (21.4%) 11 (25.6%)
Component 0.332
 na 6 (35.3%) 5 (17.9%) 11 (24.4%)
 E 1 (5.9%) 0 (0.0%) 1 (2.2%)
 E/F 3 (17.6%) 6 (21.4%) 9 (20.0%)
 E > F 1 (5.9%) 1 (3.6%) 2 (4.4%)
 F 2 (11.8%) 4 (14.3%) 6 (13.3%)
 F > E 3 (17.6%) 12 (42.9%) 15 (33.3%)
 Pure OS 1 (5.9%) 0 (0.0%) 1 (2.2%)
Stage 0.296
 nd 2 1 3
 I 1 (6.7%) 6 (22.2%) 7 (16.7%)
 II 0 (0.0%) 1 (3.7%) 1 (2.4%)
 III 9 (60.0%) 9 (33.3%) 18 (42.9%)
 IV 5 (33.3%) 11 (40.7%) 16 (38.1%)
PRETEXT 0.025
 nd 3 1 4
 1 2 (13.3%) 0 (0.0%) 2 (4.8%)
 2 3 (20.0%) 11 (40.7%) 14 (33.3%)
 3 9 (60.0%) 10 (37.0%) 19 (45.2%)
 4 0 (0.0%) 6 (22.2%) 6 (14.3%)
Extrahepatic 0.820
 nd 0 2 2
 No 16 (94.1%) 24 (92.3%) 40 (93.0%)
 Yes 1 (5.9%) 2 (7.7%) 3 (7.0%)
Multifocal 0.666
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samples displayed an enrichment of SFRP1 DNA methyla-
tion and that all tumors with a TERT mutation were SFRP1-
methylated (Fig. 3e). Of further note, SFRP1 DNA methyla-
tion as a single parameter was significantly associated with 
an older age at diagnosis, although a low SFRP1 expression 
did not correlate with the age in a simple or cumulative cor-
relation model (Fig. 3f). Overall, our findings revealed that 
SFRP1 DNA methylation and transcriptional silencing is 
a common event in pediatric liver cancer and that SFRP1 
DNA methylation is a preferential characteristic of pediatric 
liver tumors with HCC-like features, such as hepatocellular 
histology, advanced age and TERT mutations.
Discussion
A constitutive activation of the WNT/β-catenin signaling 
pathway is a common event in pediatric liver tumor devel-
opment. During embryogenesis, the pathway controls liver 
development and hepatoblast proliferation, indicating that a 
signaling malfunction contributes to liver cell transforma-
tion and tumor development (Perugorria et al. 2019). Indeed, 
HBs and HCCs exhibit an increased mutational burden in 
WNT/β-catenin pathway components that affect CTNNB1, 
APC, AXIN1 and AXIN2 genes (Tate et al. 2019). Although 
most of the mutations promote stabilization of β-catenin and 
Table 1  (continued) SFRP1 expression High (n = 17) Low (n = 28) Total (n = 45) p value
 nd 2 1 3
 No 12 (80.0%) 20 (74.1%) 32 (76.2%)
 Yes 3 (20.0%) 7 (25.9%) 10 (23.8%)
Metastasis 0.447
 nd 0 1 1
 No 12 (70.6%) 16 (59.3%) 28 (63.6%)
 Yes 5 (29.4%) 11 (40.7%) 16 (36.4%)
Chemotherapy 0.282
 No 2 (11.8%) 7 (25.0%) 9 (20.0%)
 Yes 15 (88.2%) 21 (75.0%) 36 (80.0%)
Resection margin 0.911
 Nd 2 1 3
 R0 13 (81.2%) 23 (82.1%) 36 (81.8%)
 R1 2 (12.5%) 4 (14.3%) 6 (13.6%)
16-gene signature 0.172
 na 2 (11.8%) 0 (0.0%) 2 (4.4%)
 C1 9 (52.9%) 18 (64.3%) 27 (60.0%)
 C2 6 (35.3%) 10 (35.7%) 16 (35.6%)
CTNNB1 0.017
 Mutant 11 (64.7%) 26 (92.9%) 37 (82.2%)
 Wildtype 6 (35.3%) 2 (7.1%) 8 (17.8%)
NFE2L2 0.137
 nd 3 0 3
 Mutant 0 (0.0%) 4 (14.3%) 4 (9.5%)
 Wildtype 14 (100.0%) 24 (85.7%) 38 (90.5%)
TERT 0.620
 nd 1 0 1
 Mutant 1 (6.2%) 3 (10.7%) 4 (9.1%)
 Wildtype 15 (93.8%) 25 (89.3%) 40 (90.9%)
SFRP1 methylation 0.616
 M 6 (35.3%) 12 (42.9%) 18 (40.0%)
 U 11 (64.7%) 16 (57.1%) 27 (60.0%)
Chi-square correlation analysis of normalized low (< 1) and high (> 1) SFRP1 expression categories to dif-
ferent clinicopathological and experimental parameters
m male, f female, DOD died of disease, NED no evidence of disease, HB hepatoblastoma, HCC hepatocel-
lular carcinoma, TLCT transitional liver cell tumor, NSET nested stromal-epithelial liver tumor, E embryo-
nal, F fetal, pure OS pure osteoid, C1 and C2 16-gene signature cluster C1 and C2 (Cairo et al. 2008), M 
methylated, U unmethylated, nd no data, na not applicable
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Table 2  Correlation analysis of 
SFRP1 promoter methylation SFRP1 methylation M (n = 18) U (n = 27) Total (n = 45) p value
Gender 0.021
 f 5 (27.8%) 17 (63.0%) 22 (48.9%)
 m 13 (72.2%) 10 (37.0%) 23 (51.1%)
Age at diagnosis in month  < 0.001
 nd 1 0 1
 Mean (SD) 98.48 (73.09) 31.50 (37.82) 57.38 (62.78)
 Range 7.37–199.44 0.00–156.33 0.00–199.44
Outcome 0.287
 DOD 5 (27.8%) 4 (14.8%) 9 (20.0%)
 NED 13 (72.2%) 23 (85.2%) 36 (80.0%)
Cause of death 0.512
 nd 1 0 1
 Progressive 2 (11.8%) 2 (7.4%) 4 (9.1%)
 Recurrence 3 (16.6%) 2 (7.4%) 5 (11.1%)
 Alive 12 (70.6%) 23 (85.2%) 35 (79.5%)
Tumor type 0.004
 HB 7 (38.9%) 23 (85.2%) 30 (66.7%)
 HCC/TLCT 10 (55.6%) 3 (11.1%) 13 (28.9%)
 NSET 1 (5.6%) 1 (3.7%) 2 (4.4%)
Differentiation 0.042
 nd 1 1 2
 Epithelial 8 (47.1%) 15 (57.7%) 23 (53.5%)
 Fibrolamellar 4 (23.5%) 0 (0.0%) 4 (9.3%)
 Well differentiated 1 (5.9%) 1 (3.8%) 2 (4.4%)
 Moderately differentiated 2 (11.8%) 1 (3.8%) 3 (7.0%)
 Mixed 2 (11.8%) 9 (34.6%) 11 (25.6%)
Component 0.260
 na 8 (44.4%) 3 (11.1%) 11 (24.4%)
 E 0 (0.0%) 1 (3.7%) 1 (2.2%)
 E/F 3 (16.7%) 6 (22.2%) 9 (20.0%)
 E > F 1 (5.6%) 1 (3.7%) 2 (4.4%)
 F 2 (11.1%) 4 (14.8%) 6 (13.3%)
 F > E 4 (22.2%) 11 (40.7%) 15 (33.3%)
 pure OS 0 (0.0%) 1 (3.7%) 1 (2.2%)
Stage 0.078
 nd 1 2 3
 I 5 (29.4%) 2 (8.0%) 7 (16.7%)
 II 1 (5.9%) 0 (0.0%) 1 (2.4%)
 III 4 (23.5%) 14 (56.0%) 18 (42.9%)
 IV 7 (41.2%) 9 (36.0%) 16 (38.1%)
PRETEXT 0.552
 nd 4 0 4
 1 1 (6.7%) 1 (3.7%) 2 (4.8%)
 2 6 (40.0%) 8 (29.6%) 14 (33.3%)
 3 5 (33.3%) 14 (51.9%) 19 (45.2%)
 4 2 (13.3%) 4 (14.8%) 6 (14.3%)
Extrahepatic 0.020
 nd 2 0 2
 No 13 (81.2%) 27 (100.0%) 40 (93.0%)
 Yes 3 (18.8%) 0 (0.0%) 3 (7.0%)
Multifocal 0.280
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pathway hyperactivation, several studies have reported that 
an additional epigenetic inhibition of WNT antagonists is 
important for cancer formation (Anastas and Moon 2013; 
Suzuki et al. 2008). In different tumor entities, an epigenetic 
silencing of various WNT antagonist, such as WIFs, DKKs 
and SFRPs, correlates with a poor prognosis or high-grade 
cancer (Kardum et al. 2017; Lin et al. 2017; Davaadorj et al. 
2016). Interestingly, a restoration of the WNT antagonist 
expression attenuated tumor growth (Shih et al. 2007; Gumz 
et al. 2007). In the present study, we addressed the role of 
the WNT inhibitory factor SFRP1 in HB and pediatric HCC, 
since its functional relevance has not been specified, yet. 
By determining the endogenous gene expression and DNA 
methylation status of the WNT antagonists APC, DKK1, 
SFRP1 and WIF1 in four HB cell lines, we detected a het-
erogeneous pattern. Although all four genes were methylated 
in HB cells, with the exception of DKK1 in HuH-6 cells, 
only APC and SFRP1 revealed a concomitant transcriptional 
Table 2  (continued) SFRP1 methylation M (n = 18) U (n = 27) Total (n = 45) p value
 nd 3 0 3
 No 10 (66.7%) 22 (81.5%) 32 (76.2%)
 Yes 5 (33.3%) 5 (18.5%) 10 (23.8%)
Metastasis 0.598
 nd 1 0 1
 No 10 (58.8%) 18 (66.7%) 28 (63.6%)
 Yes 7 (41.2%) 9 (33.3%) 16 (36.4%)
Chemotherapy 0.761
 No 4 (22.2%) 5 (18.5%) 9 (20.0%)
 Yes 14 (77.8%) 22 (81.5%) 36 (80.0%)
Resection margin 0.046
 nd 3 0 3
 R0 11 (64.7%) 25 (92.6%) 36 (81.8%)
 R1 4 (23.5%) 2 (7.4%) 6 (13.6%)
16-gene signature 0.871
 na 1 (5.6%) 1 (3.7%) 2 (4.4%)
 C1 10 (55.6%) 17 (63.0%) 27 (60.0%)
 C2 7 (38.9%) 9 (33.3%) 16 (35.6%)
CTNNB1 0.340
 Mutant 16 (88.9%) 21 (77.8%) 37 (82.2%)
 Wildtype 2 (11.1%) 6 (22.2%) 8 (17.8%)
NFE2L2 0.571
 nd 2 1 3
 Mutant 1 (6.2%) 3 (11.5%) 4 (9.5%)
 Wildtype 15 (93.8%) 23 (88.5%) 38 (90.5%)
TERT 0.008
 nd 1 0 1
 Mutant 4 (23.5%) 0 (0.0%) 4 (9.1%)
 Wildtype 13 (76.5%) 27 (100.0%) 40 (90.9%)
SFRP1 expression 0.908
 Mean (SD) 1.327 (1.956) 1.265 (1.575) 1.290 (1.716)
 Range 0.015–6.287 0.029–6.450 0.015–6.450
SFRP1 exp. category 0.616
 High 6 (33.3%) 11 (40.7%) 17 (37.8%)
 Low 12 (66.7%) 16 (59.3%) 28 (62.2%)
Chi-square correlation analysis of methylated (M) and unmethylated (U) SFRP1 categories to different 
clinicopathological and experimental parameters
m male, f female, DOD died of disease, NED no evidence of disease, HB hepatoblastoma, HCC hepatocel-
lular carcinoma, TLCT transitional liver cell tumor, NSET nested stromal-epithelial liver tumor, E embryo-
nal, F fetal, pure OS pure osteoid, C1 and C2 16-gene signature cluster C1 and C2 (Cairo et al. 2008), nd 
no data, na not applicable
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repression. Moreover, a treatment of the tumor cells with 
5-aza solely restored SFRP1 expression in all four cell 
lines, indicating that DNA methylation is responsible for 
the SFRP1 suppression in HB cell lines. We detected no 
involvement of histone acetylation on SFRP1 regulatory 
gene sites. Nevertheless, besides DNA methylation, histone 
modifications might control the expression of other WNT 
antagonist. Based on these results, we focused our func-
tional analyses on SFRP1 and overexpressed the gene in 
the HB cell lines HuH6, HepT1 and HepG2. In line with 
studies in HCC and other tumor entities, a re-expression of 
SFRP1 inhibited tumor cell growth, colony formation and 
migration of HB tumor cells (Shih et al. 2007; Kaur et al. 
2012; Wang et al. 2018). In contrast to Shih et al. (2007), 
our data demonstrated that cell lines which possess β-catenin 
deletion mutations, such as HepT1 and HepG2 cells, also 
exhibited canonical WNT inhibition. Interestingly, SFRP1 
re-expression diminished the canonical WNT/β-catenin 
signaling activity and we detected a downregulation of the 
WNT target genes MYC and CCND1, although the HB cell 
lines carry beta-catenin mutations. Moreover, we uncovered 
that the overall level and cellular localization of β-catenin 
is not changed after restored SFRP1 expression. Based on 
these results, we suppose that SFRP1 expression abolishes 
β-catenin-driven transcription activity. In accordance, it 
was shown that the SFRP1-mediated inhibition of the WNT 
pathway was independent from wildtype or mutant β-catenin 
in colorectal cancer cells (Suzuki et al. 2004). Hence, the 
epigenetic silencing of the Wnt antagonists SFRP1 is an 
important mechanism in pediatric liver carcinogenesis, pro-
moting WNT signaling-mediated oncogenic transformation.
Notably, in our pediatric liver cancer cohort, we detected 
a reduced SFRP1 gene expression in around 62% (28/45) 
of cases. To our knowledge, we show for the first time that 
low SFRP1 expression correlated significantly with a worse 
classification in the PRETEXT stratification system and to 
β-catenin mutations, indicating that SFRP1 gene silencing 
in β-catenin mutant cancer leads to a more aggressive cancer 
growth. SFRP1 repression might potentiate the oncogenic 
function of the WNT signaling pathway, particularly in 
β-catenin mutant cancers. Thus, a restoration of the SFRP1 
expression through epigenetic drugs or the natural com-
pound flavonoid epigallocatechin-3-gallate (EGCG), as it 
was shown in our recent study, could be a new therapeutic 
option for β-catenin mutant pediatric liver cancers (Godeke 
et al. 2013). In contrast to other studies, the reduced SFRP1 
gene expression in our HB patient cohort was not associ-
ated to the DNA methylation status (Vincent and Postovit 
2017; Kaur et al. 2012). Several patient samples showed a 
SFRP1 downregulation without a concomitant methylation 
of the promoter. With the help of the MSP, we determined 
the methylation status of only a few cytosines in the CpG 
island, thus we cannot exclude the possibility that adjacent 
cytosines might be methylated, which would result in gene 
silencing (Hernandez et al. 2013). Moreover, recent studies 
proposed a microRNA-dependent inhibition of SFRP1 in 
different cancer entities, which may also occur in pediatric 
liver cancer (Ba et al. 2017; Li et al. 2017). Overall, we iden-
tified promoter methylation of SFRP1 in 40% (18/45) of the 
analyzed cases. Importantly, the SFRP1 methylation corre-
lated with HCC-like pediatric liver tumors, with a higher age 
at diagnosis and with TERT mutations. It needs to be taken 
into consideration that these clinical features are dependent 
on each other, since the tumor manifests at older ages in the 
HCC/TLCT group (Tomlinson and Kappler 2012), which 
is furthermore characterized by frequent TERT mutations 
(Eichenmuller et al. 2014). Although in several tumor enti-
ties, SFRP1 expression or methylation was proposed as a 
prognostic biomarker (Davaadorj et al. 2016; Zheng et al. 
2015; Atschekzei et al. 2012), this was not the case for our 
cohort of pediatric liver cancers.
Conclusion
In conclusion, we delineated an important role for the epige-
netic silencing of SFRP1 in pediatric liver cancer cell lines 
and patient samples. Our data demonstrated that β-catenin 
mutant pediatric liver cancers are accompanied by a sup-
pression of the WNT antagonist SFRP1, which promotes 
malignant tumor cell characteristics. SFRP1 methylation was 
highly associated to advanced pediatric liver tumors, with 
HCC-like features and TERT mutations. However, further 
studies are needed to clarify whether SFRP1 gene expres-
sion or methylation could serve as a potential prognostic or 
diagnostic biomarker for HB or pediatric HCC.
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